National Cancer Institute Awards SBIR Contract to Rules-Based Medicine
News Dec 23, 2008
Rules-Based Medicine, Inc. (RBM) and Correlogic Systems, Inc. have announced the award of a National Cancer Institute (NCI) Small Business Innovation Research (SBIR) contract to RBM that will further research on ovarian cancer diagnostic tests.
The contract was awarded through a peer-reviewed competitive process to develop biomarker panels for the early detection of cancer and includes a Phase I Fast-Track component and Phase II option, together totaling $1.15 million.
"An early diagnostic screen for ovarian cancer could greatly increase the chances of survival," said Craig Benson, RBM's chief executive officer. "Our research will integrate additional biomarkers associated with ovarian cancer into the existing Correlogic panel with the aim of achieving sensitivity and specificity levels that can open this test to a wider population of women."
"Our search for additional biomarkers - and combinations of biomarkers - for early disease detection is an ongoing effort," said Peter Levine, Correlogic's president and chief executive officer. "We are building on Correlogic's extensive research and validation using multiple markers for disease detection to take our test to the next level."
Under the two phases of this project, RBM will develop and test quantitative, multiplexed immunoassays incorporating 19 additional analytes the two companies have identified as promising targets potentially capable of enhancing accuracy of ovarian cancer detection.
Correlogic will expand its existing analytic platform to determine the efficacy of incorporating these additional analytes into the existing assay. Upon completion RBM will add the 19 assays to its automated RBM Human Multi-Analyte Profile platform, HumanMAP®.
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019